Cyclodextrin Binding in 2-Oxo-1-Pyrrolidine Tablets
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of 2-oxo-1-pyrrolidine derivatives, such as Brivaracetam and Seletracetam, face challenges in achieving immediate release and optimal in vitro dissolution, particularly in meeting the required dissolution criteria for BCS Class I drugs, which affects their therapeutic efficacy and patient outcomes.
Innovation Solution
A pharmaceutical composition in solid tablet form incorporating 0.1% to 60% cyclodextrin as a binding agent, combined with Brivaracetam or Seletracetam, along with disintegrants, diluents, and lubricants, is developed to ensure immediate release and compliance with in vitro dissolution standards, utilizing a direct compression process that reduces sticking and requires lower compression pressures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional pharmaceutical compositions are used, then the formulation is simple, but the in vitro dissolution rate is insufficient to meet immediate release criteria
Solution Approach 1:
Cyclodextrin is introduced as an intermediary substance that forms inclusion complexes with 2-oxo-1-pyrrolidine derivatives, enhancing the dissolution rate without requiring complex formulation changes. The cyclodextrin acts as a mediator between the drug and the dissolution medium, solving the contradiction between simple formulation and high dissolution rate.
Solution Approach 2:
The formulation changes the physical-chemical parameters by incorporating cyclodextrin, which alters the dissolution characteristics of the drug. This parameter change enables immediate release performance while maintaining a relatively simple tablet formulation structure.
2Strength
If compression pressure is increased to improve tablet binding, then tablet strength increases, but drug dissolution is hindered
Solution Approach 1:
Cyclodextrin serves as a binding intermediary that provides adequate tablet strength at lower compression pressures. By forming inclusion complexes, cyclodextrin enhances binding without requiring high compression forces that would otherwise compact the drug particles and hinder dissolution.
Solution Approach 2:
The use of cyclodextrin changes the compression parameter requirements, allowing tablet formation at lower pressures while maintaining both strength and dissolution performance. This parameter change resolves the contradiction between tablet strength and drug dissolution.
3Stability of the object's composition
If high compression pressure is applied during tabletting, then binding is improved, but sticking occurs and dissolution is reduced
Solution Approach 1:
Cyclodextrin acts as a binding intermediary that reduces direct particle-to-particle contact during compression, minimizing sticking. The inclusion complexes formed by cyclodextrin provide binding without the harmful sticking effects associated with high compression of pure drug particles.
Solution Approach 2:
The formulation changes the compression behavior by incorporating cyclodextrin, which modifies the pressure-density relationship during tabletting. This parameter change allows achieving binding at lower pressures, avoiding the sticking phenomenon and preserving dissolution characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective immediate release and high in vitro dissolution rates, meeting the necessary dissolution criteria, thereby enhancing therapeutic efficacy and patient outcomes, with the cyclodextrin agent improving binding and drug dissolution without forming inclusion complexes.
Implementation Method 1
incorporating 0.1% to 60% cyclodextrin as a binding agent
Implementation Method 2
achieves effective immediate release and high in vitro dissolution rates
Data Source
AI summary
The present invention relates to an immediate release formulation of pharmaceutical compounds.